Walleye Capital LLC Akebia Therapeutics, Inc. Transaction History

Walleye Capital LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Mar 03, 2022	SELL	$2.26 - $3.34 $624,347 - $922,708	-276,260 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $108,553 - $179,228	-46,193 Reduced 14.33%	276,260 $796,000
Q2 2021 Aug 16, 2021	BUY	$2.83 - $4.2 $739,875 - $1.1 Million	261,440 Added 428.5%	322,453 $1.22 Million
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $3,127 - $5,419	1,071 Added 1.79%	61,013 $207,000
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $118,077 - $201,050	-53,188 Reduced 47.01%	59,942 $168,000
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $270,380 - $1.48 Million	113,130 New	113,130 $284,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $23,444 - $49,929	-7,419 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $20,217 - $30,753	5,695 Added 330.34%	7,419 $29,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $7,068 - $13,878	1,724 New	1,724 $8,000

121

54.6M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $349M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.